CAD and neoplasm: In combination with the inclusion of synthetic mRNAs, these mixed assembly VLPs could also be utilized as powerful RNA therapeutics technologies with dual effector actions, such as modifying the surface CPs with tumor-targeting ligands and encapsulating mRNAs encoding a therapeutic cytokine, where payloads and surface properties could be used to achieve a combined therapeutic aim.